Cerebral complications in preeclampsia are one of the major causes of maternal mortality and morbidity. In addition, women with previous preeclampsia run an increased risk of neurological disorders later in life such as stroke, epilepsy and possibly neurocognitive disorders and dementia. There are gaps in knowledge regarding underlying pathophysiological mechanisms to short-and long-term neurological complications in preeclampsia. In addition, there is a need for more accurate predictive and diagnostic tools to identify women at high risk. Also, therapeutic options are limited.
The goal of this Research Topic is to highlight cerebral complications in women with preeclampsia and concentrate the evidence around pathophysiological pathways. This can be achieved by assembling information from suitable pre-clinical models describing the condition including potential underlying causes and established and new therapeutics. In addition, clinical studies and register-based studies can provide more information about potential diagnostic and prognostic tools and phenotyping of the disease.
Pre-clinical and clinical manuscripts addressing the issues above. Systematic reviews with a well defined PICO regarding cerebral complications to preeclampsia are also welcome.
Roche and Perkin Elmer provide free reagents of sFlt-1 and PlGF to the IMPACT study for first trimester prediction of preeclampsia where Dr Bergman is co-investigator. The companies have no involvement in the design, conduct or reporting of the study.
Cerebral complications in preeclampsia are one of the major causes of maternal mortality and morbidity. In addition, women with previous preeclampsia run an increased risk of neurological disorders later in life such as stroke, epilepsy and possibly neurocognitive disorders and dementia. There are gaps in knowledge regarding underlying pathophysiological mechanisms to short-and long-term neurological complications in preeclampsia. In addition, there is a need for more accurate predictive and diagnostic tools to identify women at high risk. Also, therapeutic options are limited.
The goal of this Research Topic is to highlight cerebral complications in women with preeclampsia and concentrate the evidence around pathophysiological pathways. This can be achieved by assembling information from suitable pre-clinical models describing the condition including potential underlying causes and established and new therapeutics. In addition, clinical studies and register-based studies can provide more information about potential diagnostic and prognostic tools and phenotyping of the disease.
Pre-clinical and clinical manuscripts addressing the issues above. Systematic reviews with a well defined PICO regarding cerebral complications to preeclampsia are also welcome.
Roche and Perkin Elmer provide free reagents of sFlt-1 and PlGF to the IMPACT study for first trimester prediction of preeclampsia where Dr Bergman is co-investigator. The companies have no involvement in the design, conduct or reporting of the study.
